Immune checkpoint inhibitor therapy targeting programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) is a novel tumor immunotherapy approach that can reverse tumor immune escape [8]. The gene discussed is CD274; the disease is neoplasm.